Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.67 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 3/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857624 | 0.84 | BRD4 (0.71) | BRD4NT5C2CREBBPAURKA | |
| SCHEMBL29514799 | 0.81 | BRD4 (1.00) | BRD4NT5C2NT5ECREBBPBTK | |
| SCHEMBL23124 | 0.81 | BRD4 (1.00) | BRD4NT5C2NT5ECREBBPBTK | |
| SCHEMBL8381776 | 0.80 | BRD4 (0.97) | BRD4NT5C2NT5ECREBBPBTK | |
| SCHEMBL7717445 | 0.80 | BRD4 (0.51) | BRD4NT5C2NT5EHTT | |
| SCHEMBL2346676 | 0.79 | MKNK1 (0.41) | BRD4NT5C2NT5ETOP2A | |
| SCHEMBL8121393 | 0.78 | STAT3 (0.69) | BRD4NT5C2NT5ESTAT3CREBBP | |
| SCHEMBL5694052 | 0.78 | BRD4 (0.67) | BRD4NT5C2NT5ESTAT3CREBBP | |
| SCHEMBL5860314 | 0.78 | POLB (0.45) | BRD4HTT | |
| SCHEMBL5858886 | 0.78 | BRD4 (0.42) | BRD4NT5C2NT5ECREBBPTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | claimed |
| US-6649750-B1 | Nucleoside linked to a support through heterocyclic base and amide bond; deblocking/deprotecting; capping/oxidizing; purity; reduced levels of byproducts containing abasic sites | ISIS PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | claimed |
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | claimed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | claimed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | claimed |
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | disclosed |
| US-6380378-B1 | BIOSYNTHESIS | TOAGOSEI COMPANY, LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | disclosed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | disclosed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | PPM1A, PPM1G, PPM1F | BRD4 1684/4885NT5C2 3957/4885NT5E 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.